vs
COMERICA INC（CMA）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
COMERICA INC的季度营收约是Royalty Pharma plc的1.3倍（$838.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 21.0%，领先13.4%），Royalty Pharma plc同比增速更快（4.8% vs 3.3%），过去两年COMERICA INC的营收复合增速更高（108.9% vs 4.6%）
Comerica公司是总部位于美国得克萨斯州达拉斯的金融服务企业，为美国大型金融控股公司之一。旗下Comerica银行为区域性商业银行，在得克萨斯、密歇根、加利福尼亚、佛罗里达、亚利桑那五州共设413家网点，在美国多座城市设有办公场所。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CMA vs RPRX — 直观对比
营收规模更大
CMA
是对方的1.3倍
$622.0M
营收增速更快
RPRX
高出1.4%
3.3%
净利率更高
RPRX
高出13.4%
21.0%
两年增速更快
CMA
近两年复合增速
4.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $838.0M | $622.0M |
| 净利润 | $176.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | — | 62.4% |
| 净利率 | 21.0% | 34.4% |
| 营收同比 | 3.3% | 4.8% |
| 净利润同比 | -4.3% | 2.9% |
| 每股收益（稀释后） | $1.35 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMARPRX
| Q4 25 | — | $622.0M | ||
| Q3 25 | $838.0M | $609.3M | ||
| Q2 25 | $849.0M | $578.7M | ||
| Q1 25 | $829.0M | $568.2M | ||
| Q4 24 | $825.0M | $593.6M | ||
| Q3 24 | $811.0M | $564.7M | ||
| Q2 24 | $824.0M | $537.3M | ||
| Q1 24 | $784.0M | $568.0M |
净利润CMARPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | $176.0M | $288.2M | ||
| Q2 25 | $199.0M | $30.2M | ||
| Q1 25 | $172.0M | $238.3M | ||
| Q4 24 | $170.0M | $208.2M | ||
| Q3 24 | $184.0M | $544.0M | ||
| Q2 24 | $206.0M | $102.0M | ||
| Q1 24 | $138.0M | $4.8M |
营业利润率CMARPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率CMARPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | 21.0% | 47.3% | ||
| Q2 25 | 23.4% | 5.2% | ||
| Q1 25 | 20.7% | 41.9% | ||
| Q4 24 | 20.6% | 35.1% | ||
| Q3 24 | 22.7% | 96.3% | ||
| Q2 24 | 25.0% | 19.0% | ||
| Q1 24 | 17.6% | 0.8% |
每股收益（稀释后）CMARPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $1.35 | $0.67 | ||
| Q2 25 | $1.42 | $0.07 | ||
| Q1 25 | $1.25 | $0.55 | ||
| Q4 24 | $1.22 | $0.46 | ||
| Q3 24 | $1.33 | $1.21 | ||
| Q2 24 | $1.49 | $0.23 | ||
| Q1 24 | $0.98 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $5.4B | $9.0B |
| 股东权益账面价值 | $7.4B | $9.7B |
| 总资产 | $77.4B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.73× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CMARPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务CMARPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $5.4B | $8.9B | ||
| Q2 25 | $5.8B | $8.0B | ||
| Q1 25 | $5.7B | $7.6B | ||
| Q4 24 | $6.7B | $7.6B | ||
| Q3 24 | $6.8B | $7.6B | ||
| Q2 24 | $7.1B | $7.6B | ||
| Q1 24 | $7.1B | $6.1B |
股东权益CMARPRX
| Q4 25 | — | $9.7B | ||
| Q3 25 | $7.4B | $9.6B | ||
| Q2 25 | $6.9B | $9.5B | ||
| Q1 25 | $7.1B | $9.8B | ||
| Q4 24 | $6.5B | $10.3B | ||
| Q3 24 | $7.4B | $10.3B | ||
| Q2 24 | $6.2B | $9.8B | ||
| Q1 24 | $6.0B | $9.9B |
总资产CMARPRX
| Q4 25 | — | $19.6B | ||
| Q3 25 | $77.4B | $19.3B | ||
| Q2 25 | $78.0B | $18.3B | ||
| Q1 25 | $77.6B | $17.6B | ||
| Q4 24 | $79.3B | $18.2B | ||
| Q3 24 | $79.7B | $18.0B | ||
| Q2 24 | $79.6B | $17.7B | ||
| Q1 24 | $79.4B | $16.1B |
负债/权益比CMARPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.73× | 0.93× | ||
| Q2 25 | 0.84× | 0.84× | ||
| Q1 25 | 0.81× | 0.78× | ||
| Q4 24 | 1.02× | 0.74× | ||
| Q3 24 | 0.92× | 0.74× | ||
| Q2 24 | 1.15× | 0.78× | ||
| Q1 24 | 1.18× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-270.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -1.53× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CMARPRX
| Q4 25 | — | $827.1M | ||
| Q3 25 | $-270.0M | $702.6M | ||
| Q2 25 | $476.0M | $364.0M | ||
| Q1 25 | $273.0M | $596.1M | ||
| Q4 24 | $601.0M | $742.5M | ||
| Q3 24 | $1.0B | $703.6M | ||
| Q2 24 | $111.0M | $658.2M | ||
| Q1 24 | $-205.0M | $664.6M |
现金转化率CMARPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | -1.53× | 2.44× | ||
| Q2 25 | 2.39× | 12.06× | ||
| Q1 25 | 1.59× | 2.50× | ||
| Q4 24 | 3.54× | 3.57× | ||
| Q3 24 | 5.70× | 1.29× | ||
| Q2 24 | 0.54× | 6.45× | ||
| Q1 24 | -1.49× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMA
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
